Variable | Taurine group (n = 60) | Placebo group (n = 60) | MD (95% CI), P-value |
---|---|---|---|
TAC (mmol/L) | |||
 Before | 126.85 ± 39.82 | 131.36 ± 38.83 | 4.5 (−18.86 to 8.79), 0.531a |
 After | 192.61 ± 91.77 | 147.52 ± 107.12 | 45 (9. 6 to 81.1), 0.015b |
 MD (95% CI), P-valuec | 65.73 (41.7 to 88.8), 0.001 | 16.54 (−11.7 to 44.7), 0.256 |  |
MDA (nmol/mL) | |||
 Before | 170.79 ± 61.47 | 183.38 ± 125.08 | −12.20 (–48.7 to 12.33), 0.485a |
 After | 129.61 ± 109.60 | 172.46 ± 128.19 | −43.6 (−83.7 to −3.57), 0.033b |
 MD (95% CI), P-valuec | −41.70 (−69.6 to −11.74), 0.007 | −10.29 (−32.9 to 24.4), 0.614 |  |
HsCRPÂ (mg/dL) | |||
 Before | 3.17 ± 1.88 | 3.01 ± 1.79 | 0.41 (−0.55 to 0.85), 0.642a |
 After | 1.87 ± 2.08 | 3.66 ± 3.17 | 1.76 (−2.7 to −0.88), 0.001b |
 MD (95% CI), P-valuec | −1.29 (−2.6 to −0.54), 0.001 | −0.64 (−0.50 to 1.25), 0.157 |  |
TNF-alpha (ng/ml) | |||
 Before | 33.18 ± 25.27 | 30.90 ± 24.53 | 2.28 (−6.66 to 10.45), 0.616a |
 After | 14.42 ± 10.50 | 25.82 ± 26.27 | 11.01 (−18.3 to −4.3), 0.002b |
 MD (95% CI), P-valuec | −18.74 (−20.6 to −11.87), 0.001 | −5.07 (−14.50 to 420), 0.291 |  |